<!-- KEYWORD_LINKING_METADATA:
{
  "processed_timestamp": "2025-09-24T13:37:21.575112",
  "vocabulary_version": "1.0",
  "selected_keywords": [
    "Machine Learning",
    "Pathway Mapping",
    "Therapeutic Target Discovery",
    "Insulin Signaling Pathway",
    "Pima Indian Dataset"
  ],
  "rejected_keywords": [],
  "similarity_scores": {
    "Machine Learning": 0.85,
    "Pathway Mapping": 0.8,
    "Therapeutic Target Discovery": 0.75,
    "Insulin Signaling Pathway": 0.78,
    "Pima Indian Dataset": 0.7
  },
  "extraction_method": "AI_prompt_based",
  "budget_applied": true,
  "candidates_json": {
    "candidates": [
      {
        "surface": "Machine Learning",
        "canonical": "Machine Learning",
        "aliases": [
          "ML"
        ],
        "category": "broad_technical",
        "rationale": "Machine Learning is a foundational technique used in the framework, connecting it to broader technical discussions.",
        "novelty_score": 0.45,
        "connectivity_score": 0.9,
        "specificity_score": 0.5,
        "link_intent_score": 0.85
      },
      {
        "surface": "Pathway Mapping",
        "canonical": "Pathway Mapping",
        "aliases": [
          "Gene-Agnostic Pathway Mapping"
        ],
        "category": "unique_technical",
        "rationale": "Pathway Mapping is a novel approach in the study that bridges predictive analytics with biological relevance.",
        "novelty_score": 0.75,
        "connectivity_score": 0.7,
        "specificity_score": 0.8,
        "link_intent_score": 0.8
      },
      {
        "surface": "Therapeutic Target Discovery",
        "canonical": "Therapeutic Target Discovery",
        "aliases": [
          "Target Discovery"
        ],
        "category": "unique_technical",
        "rationale": "This is a key outcome of the framework, providing a unique angle on precision medicine.",
        "novelty_score": 0.7,
        "connectivity_score": 0.65,
        "specificity_score": 0.78,
        "link_intent_score": 0.75
      },
      {
        "surface": "Insulin Signaling Pathway",
        "canonical": "Insulin Signaling Pathway",
        "aliases": [
          "Insulin Pathway"
        ],
        "category": "specific_connectable",
        "rationale": "The Insulin Signaling Pathway is critical to the study's focus on metabolic disorders, offering specific biological insights.",
        "novelty_score": 0.55,
        "connectivity_score": 0.8,
        "specificity_score": 0.85,
        "link_intent_score": 0.78
      },
      {
        "surface": "Pima Indian Dataset",
        "canonical": "Pima Indian Dataset",
        "aliases": [
          "Pima Dataset"
        ],
        "category": "unique_technical",
        "rationale": "This dataset is central to the study's analysis, providing a unique context for the research.",
        "novelty_score": 0.8,
        "connectivity_score": 0.6,
        "specificity_score": 0.9,
        "link_intent_score": 0.7
      }
    ],
    "ban_list_suggestions": [
      "Metabolic Disorders",
      "Type 2 Diabetes Mellitus"
    ]
  },
  "decisions": [
    {
      "candidate_surface": "Machine Learning",
      "resolved_canonical": "Machine Learning",
      "decision": "linked",
      "scores": {
        "novelty": 0.45,
        "connectivity": 0.9,
        "specificity": 0.5,
        "link_intent": 0.85
      }
    },
    {
      "candidate_surface": "Pathway Mapping",
      "resolved_canonical": "Pathway Mapping",
      "decision": "linked",
      "scores": {
        "novelty": 0.75,
        "connectivity": 0.7,
        "specificity": 0.8,
        "link_intent": 0.8
      }
    },
    {
      "candidate_surface": "Therapeutic Target Discovery",
      "resolved_canonical": "Therapeutic Target Discovery",
      "decision": "linked",
      "scores": {
        "novelty": 0.7,
        "connectivity": 0.65,
        "specificity": 0.78,
        "link_intent": 0.75
      }
    },
    {
      "candidate_surface": "Insulin Signaling Pathway",
      "resolved_canonical": "Insulin Signaling Pathway",
      "decision": "linked",
      "scores": {
        "novelty": 0.55,
        "connectivity": 0.8,
        "specificity": 0.85,
        "link_intent": 0.78
      }
    },
    {
      "candidate_surface": "Pima Indian Dataset",
      "resolved_canonical": "Pima Indian Dataset",
      "decision": "linked",
      "scores": {
        "novelty": 0.8,
        "connectivity": 0.6,
        "specificity": 0.9,
        "link_intent": 0.7
      }
    }
  ]
}
-->

# A Machine Learning Framework for Pathway-Driven Therapeutic Target Discovery in Metabolic Disorders

## ğŸ“‹ ë©”íƒ€ë°ì´í„°

**Links**: [[daily_digest_20250924|20250924]] [[categories/cs.AI|cs.AI]]
**PDF**: [Download](https://arxiv.org/pdf/2509.18140.pdf)
**Category**: cs.AI
**Published**: 2025-09-24
**ArXiv ID**: [2509.18140](https://arxiv.org/abs/2509.18140)

## ğŸ”— ìœ ì‚¬í•œ ë…¼ë¬¸
- [[2025-09-22/Temperature-Driven Robust Disease Detection in Brain and Gastrointestinal Disorders via Context-Aware Adaptive Knowledge Distillation_20250922|Temperature-Driven Robust Disease Detection in Brain and Gastrointestinal Disorders via Context-Aware Adaptive Knowledge Distillation]] (79.3% similar)
- [[2025-09-23/MRN_ Harnessing 2D Vision Foundation Models for Diagnosing Parkinson's Disease with Limited 3D MR Data_20250923|MRN: Harnessing 2D Vision Foundation Models for Diagnosing Parkinson's Disease with Limited 3D MR Data]] (79.3% similar)
- [[2025-09-24/Model selection meets clinical semantics_ Optimizing ICD-10-CM prediction via LLM-as-Judge evaluation, redundancy-aware sampling, and section-aware fine-tuning_20250924|Model selection meets clinical semantics: Optimizing ICD-10-CM prediction via LLM-as-Judge evaluation, redundancy-aware sampling, and section-aware fine-tuning]] (79.1% similar)
- [[2025-09-23/System-Level Uncertainty Quantification with Multiple Machine Learning Models_ A Theoretical Framework_20250923|System-Level Uncertainty Quantification with Multiple Machine Learning Models: A Theoretical Framework]] (79.0% similar)
- [[2025-09-23/Medical priority fusion_ achieving dual optimization of sensitivity and interpretability in nipt anomaly detection_20250923|Medical priority fusion: achieving dual optimization of sensitivity and interpretability in nipt anomaly detection]] (79.0% similar)

## ğŸ·ï¸ ì¹´í…Œê³ ë¦¬í™”ëœ í‚¤ì›Œë“œ
**ğŸ§  Broad Technical**: [[keywords/Machine Learning|Machine Learning]]
**ğŸ”— Specific Connectable**: [[keywords/Insulin Signaling Pathway|Insulin Signaling Pathway]]
**âš¡ Unique Technical**: [[keywords/Pathway Mapping|Pathway Mapping]], [[keywords/Therapeutic Target Discovery|Therapeutic Target Discovery]], [[keywords/Pima Indian Dataset|Pima Indian Dataset]]

## ğŸ“‹ ì €ì ì •ë³´

**Authors:** 

## ğŸ“„ Abstract (ì›ë¬¸)

arXiv:2509.18140v1 Announce Type: cross 
Abstract: Metabolic disorders, particularly type 2 diabetes mellitus (T2DM), represent a significant global health burden, disproportionately impacting genetically predisposed populations such as the Pima Indians (a Native American tribe from south central Arizona). This study introduces a novel machine learning (ML) framework that integrates predictive modeling with gene-agnostic pathway mapping to identify high-risk individuals and uncover potential therapeutic targets. Using the Pima Indian dataset, logistic regression and t-tests were applied to identify key predictors of T2DM, yielding an overall model accuracy of 78.43%. To bridge predictive analytics with biological relevance, we developed a pathway mapping strategy that links identified predictors to critical signaling networks, including insulin signaling, AMPK, and PPAR pathways. This approach provides mechanistic insights without requiring direct molecular data. Building upon these connections, we propose therapeutic strategies such as dual GLP-1/GIP receptor agonists, AMPK activators, SIRT1 modulators, and phytochemical, further validated through pathway enrichment analyses. Overall, this framework advances precision medicine by offering interpretable and scalable solutions for early detection and targeted intervention in metabolic disorders. The key contributions of this work are: (1) development of an ML framework combining logistic regression and principal component analysis (PCA) for T2DM risk prediction; (2) introduction of a gene-agnostic pathway mapping approach to generate mechanistic insights; and (3) identification of novel therapeutic strategies tailored for high-risk populations.

## ğŸ“ ìš”ì•½

ì´ ì—°êµ¬ëŠ” Pima ì¸ë””ì–¸ì„ ëŒ€ìƒìœ¼ë¡œ í•œ ë°ì´í„°ì…‹ì„ í™œìš©í•˜ì—¬ ì œ2í˜• ë‹¹ë‡¨ë³‘(T2DM) ê³ ìœ„í—˜êµ°ì„ ì‹ë³„í•˜ê³  ì ì¬ì  ì¹˜ë£Œ í‘œì ì„ ë°œê²¬í•˜ê¸° ìœ„í•œ ìƒˆë¡œìš´ ë¨¸ì‹ ëŸ¬ë‹(ML) í”„ë ˆì„ì›Œí¬ë¥¼ ì œì•ˆí•©ë‹ˆë‹¤. ë¡œì§€ìŠ¤í‹± íšŒê·€ì™€ t-ê²€ì •ì„ í†µí•´ T2DMì˜ ì£¼ìš” ì˜ˆì¸¡ ë³€ìˆ˜ë¥¼ ì‹ë³„í•˜ì—¬ 78.43%ì˜ ëª¨ë¸ ì •í™•ë„ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì˜ˆì¸¡ ë¶„ì„ê³¼ ìƒë¬¼í•™ì  ê´€ë ¨ì„±ì„ ì—°ê²°í•˜ê¸° ìœ„í•´ ì¸ìŠë¦° ì‹ í˜¸, AMPK, PPAR ê²½ë¡œì™€ ê°™ì€ ì¤‘ìš”í•œ ì‹ í˜¸ ë„¤íŠ¸ì›Œí¬ì™€ ì˜ˆì¸¡ ë³€ìˆ˜ë¥¼ ì—°ê²°í•˜ëŠ” ê²½ë¡œ ë§¤í•‘ ì „ëµì„ ê°œë°œí–ˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ë¶„ì ë°ì´í„° ì—†ì´ë„ ê¸°ì „ì  í†µì°°ì„ ì œê³µí•©ë‹ˆë‹¤. ë˜í•œ, GLP-1/GIP ìˆ˜ìš©ì²´ ì‘ìš©ì œ, AMPK í™œì„±í™”ì œ, SIRT1 ì¡°ì ˆì œ, ì‹ë¬¼ í™”í•™ë¬¼ì§ˆê³¼ ê°™ì€ ì¹˜ë£Œ ì „ëµì„ ì œì•ˆí•˜ê³  ê²½ë¡œ ê°•í™” ë¶„ì„ì„ í†µí•´ ì´ë¥¼ ê²€ì¦í–ˆìŠµë‹ˆë‹¤. ì£¼ìš” ê¸°ì—¬ëŠ” (1) ë¡œì§€ìŠ¤í‹± íšŒê·€ì™€ ì£¼ì„±ë¶„ ë¶„ì„(PCA)ì„ ê²°í•©í•œ T2DM ìœ„í—˜ ì˜ˆì¸¡ ML í”„ë ˆì„ì›Œí¬ ê°œë°œ, (2) ê¸°ì „ì  í†µì°°ì„ ì œê³µí•˜ëŠ” ìœ ì „ì ë¹„íŠ¹ì´ì  ê²½ë¡œ ë§¤í•‘ ì ‘ê·¼ë²• ë„ì…, (3) ê³ ìœ„í—˜êµ°ì— ë§ì¶˜ ìƒˆë¡œìš´ ì¹˜ë£Œ ì „ëµ ì‹ë³„ì…ë‹ˆë‹¤.

## ğŸ¯ ì£¼ìš” í¬ì¸íŠ¸

- 1. ì´ ì—°êµ¬ëŠ” ìœ ì „ì ë¹„íŠ¹ì´ì  ê²½ë¡œ ë§¤í•‘ê³¼ ì˜ˆì¸¡ ëª¨ë¸ë§ì„ í†µí•©í•œ ìƒˆë¡œìš´ ê¸°ê³„ í•™ìŠµ í”„ë ˆì„ì›Œí¬ë¥¼ ì œì•ˆí•˜ì—¬ T2DM ê³ ìœ„í—˜êµ°ì„ ì‹ë³„í•˜ê³  ì ì¬ì  ì¹˜ë£Œ í‘œì ì„ ë°œê²¬í•©ë‹ˆë‹¤.
- 2. Pima ì¸ë””ì–¸ ë°ì´í„°ë¥¼ ì‚¬ìš©í•˜ì—¬ ë¡œì§€ìŠ¤í‹± íšŒê·€ì™€ t-í…ŒìŠ¤íŠ¸ë¥¼ í†µí•´ T2DMì˜ ì£¼ìš” ì˜ˆì¸¡ ë³€ìˆ˜ë¥¼ ì‹ë³„í•˜ê³ , ëª¨ë¸ì˜ ì „ì²´ ì •í™•ë„ëŠ” 78.43%ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤.
- 3. ì˜ˆì¸¡ ë¶„ì„ê³¼ ìƒë¬¼í•™ì  ê´€ë ¨ì„±ì„ ì—°ê²°í•˜ê¸° ìœ„í•´ ì¸ìŠë¦° ì‹ í˜¸, AMPK, PPAR ê²½ë¡œë¥¼ í¬í•¨í•œ ì¤‘ìš”í•œ ì‹ í˜¸ ë„¤íŠ¸ì›Œí¬ì™€ ì˜ˆì¸¡ ë³€ìˆ˜ë¥¼ ì—°ê²°í•˜ëŠ” ê²½ë¡œ ë§¤í•‘ ì „ëµì„ ê°œë°œí–ˆìŠµë‹ˆë‹¤.
- 4. ì´ ì—°êµ¬ëŠ” GLP-1/GIP ìˆ˜ìš©ì²´ ì‘ìš©ì œ, AMPK í™œì„±ì œ, SIRT1 ì¡°ì ˆì œ ë° ì‹ë¬¼ í™”í•™ ë¬¼ì§ˆê³¼ ê°™ì€ ì¹˜ë£Œ ì „ëµì„ ì œì•ˆí•˜ê³ , ê²½ë¡œ ê°•í™” ë¶„ì„ì„ í†µí•´ ì´ë¥¼ ì¶”ê°€ë¡œ ê²€ì¦í–ˆìŠµë‹ˆë‹¤.
- 5. ì´ í”„ë ˆì„ì›Œí¬ëŠ” T2DM ìœ„í—˜ ì˜ˆì¸¡ì„ ìœ„í•œ ë¡œì§€ìŠ¤í‹± íšŒê·€ì™€ ì£¼ì„±ë¶„ ë¶„ì„(PCA)ì„ ê²°í•©í•œ ML í”„ë ˆì„ì›Œí¬ ê°œë°œ, ê¸°ê³„ì  í†µì°°ì„ ìƒì„±í•˜ëŠ” ìœ ì „ì ë¹„íŠ¹ì´ì  ê²½ë¡œ ë§¤í•‘ ì ‘ê·¼ë²• ë„ì…, ê³ ìœ„í—˜êµ°ì— ë§ì¶˜ ìƒˆë¡œìš´ ì¹˜ë£Œ ì „ëµ ì‹ë³„ì„ ì£¼ìš” ê¸°ì—¬ë¡œ í•©ë‹ˆë‹¤.


---

*Generated on 2025-09-24 13:37:21*